These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32513767)

  • 1. Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin).
    Latif A; Gastelum AA; Sood A; Reddy JT
    BMJ Case Rep; 2020 Jun; 13(6):. PubMed ID: 32513767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ketogenic diet as a trigger for diabetic euglycaemic ketoacidosis in a patient under treatment with iSGLT2].
    Nubiola A; Ternianov A; Remolins I
    Hipertens Riesgo Vasc; 2020; 37(1):39-41. PubMed ID: 31734176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin-associated euglycemic diabetic ketoacidosis in a patient with type 2 diabetes mellitus: A case report.
    Lee IH; Ahn DJ
    Medicine (Baltimore); 2020 May; 99(21):e20228. PubMed ID: 32481295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment.
    Storgaard H; Bagger JI; Knop FK; Vilsbøll T; Rungby J
    Basic Clin Pharmacol Toxicol; 2016 Feb; 118(2):168-70. PubMed ID: 26291182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Euglycemic diabetic ketoacidosis caused by dapagliflozin: A case report.
    Chou YM; Seak CJ; Goh ZNL; Seak JC; Seak CK; Lin CC
    Medicine (Baltimore); 2018 Jun; 97(25):e11056. PubMed ID: 29923997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Euglycaemic diabetic ketoacidosis in a patient with type 2 diabetes started on empagliflozin.
    Rashid O; Farooq S; Kiran Z; Islam N
    BMJ Case Rep; 2016 May; 2016():. PubMed ID: 27177938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Life-threatening ketoacidosis in a 25-year-old woman treated with sodium-glucose cotransporter 2 inhibitor].
    Lindberg MJ; Kristensen FB; Yildiz A
    Ugeskr Laeger; 2016 Nov; 178(47):. PubMed ID: 27908315
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Euglycemic diabetic ketoacidosis in type 2 diabetes with sodium glucose cotransporter 2 inhibitors.
    Wang AY; Hou SK; Li SJ; Kao WF
    Am J Emerg Med; 2017 Feb; 35(2):379.e5-379.e6. PubMed ID: 27614369
    [No Abstract]   [Full Text] [Related]  

  • 9. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
    Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
    BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.
    Bilgin S; Duman TT; Kurtkulagi O; Yilmaz F; Aktas G
    J Coll Physicians Surg Pak; 2022 Jul; 32(7):928-930. PubMed ID: 35795946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic.
    Ozer O; Yorulmaz G
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):110-111. PubMed ID: 33115581
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN.
    Ahmed M; McKenna MJ; Crowley RK
    Endocr Pract; 2017 Apr; 23(4):506-508. PubMed ID: 28437153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Euglycaemic diabetic ketoacidosis in a patient with pancreatitis and type 2 diabetes on empagliflozin.
    Bardhi O; Bloom MD; Sattari M
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35732358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
    Peters AL; Buschur EO; Buse JB; Cohan P; Diner JC; Hirsch IB
    Diabetes Care; 2015 Sep; 38(9):1687-93. PubMed ID: 26078479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin Use: A Case Report.
    Brown F; McColl T
    J Emerg Med; 2018 Jan; 54(1):109-111. PubMed ID: 29157798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very low carbohydrate diet and SGLT-2-inhibitor: double jeopardy in relation to ketoacidosis.
    Tougaard NH; Faber J; Eldrup E
    BMJ Case Rep; 2019 Apr; 12(4):. PubMed ID: 30954957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in the Diagnosis of Euglycemic Diabetic Ketoacidosis in a Patient With Multiple Sclerosis Taking a Sodium-Glucose Cotransporter 2 Inhibitor.
    Allison R; Goldstein D; Musso MW
    J Emerg Med; 2019 Jul; 57(1):e1-e3. PubMed ID: 31027990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.
    Burke KR; Schumacher CA; Harpe SE
    Pharmacotherapy; 2017 Feb; 37(2):187-194. PubMed ID: 27931088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.